Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
AC Immune SA ( (ACIU) ) has shared an announcement.
On November 4, 2025, AC Immune SA released its interim financial results for the three and nine months ending September 30, 2025. The report highlighted a significant decline in revenue compared to the previous year, with the company experiencing a loss for the period. This financial performance reflects ongoing challenges in the biopharmaceutical industry, impacting the company’s market position and stakeholder confidence.
The most recent analyst rating on (ACIU) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on AC Immune SA stock, see the ACIU Stock Forecast page.
Spark’s Take on ACIU Stock
According to Spark, TipRanks’ AI Analyst, ACIU is a Neutral.
The overall stock score for ACIU is primarily influenced by its financial performance and technical analysis. The company shows potential with improving cash flow and stable balance sheet, but ongoing net losses and valuation concerns weigh down the score. Positive market momentum provides some optimism, but the lack of profitability and valuation challenges remain significant risks.
To see Spark’s full report on ACIU stock, click here.
More about AC Immune SA
AC Immune SA is a Swiss-based biopharmaceutical company that specializes in developing precision medicine for neurodegenerative diseases. The company focuses on creating innovative therapeutic and diagnostic products aimed at addressing conditions such as Alzheimer’s disease.
Average Trading Volume: 255,120
Technical Sentiment Signal: Buy
Current Market Cap: $314.6M
Find detailed analytics on ACIU stock on TipRanks’ Stock Analysis page.